Image Credit: Health and me
Pregnancy is accompanied by a lengthy list of do's and don'ts—take prenatal vitamins, no alcohol, exercise carefully, and eat well. But what about when an unplanned health issue presents itself, such as the necessity for a mammogram? For most women, this might not even be something they think about until they are in a position where breast cancer screening is an option.
Perhaps you're over 40 and in need of your yearly mammogram, or perhaps you have a history of breast cancer in your family and you want to keep your screenings current. More emergently, you've found a lump in your breast. So, can you have a mammogram when pregnant? The answer is yes, but there are several things to consider.
Pregnancy creates substantial hormonal changes that affect the body, as well as breast tissue. Estrogen and progesterone's rise causes the breasts to expand and condition to produce milk, which results in denser tissue. This increased density is more challenging to detect any abnormalities with using mammograms. Even post-delivery, should the woman be breastfeeding, milk-filled glands can also make the breasts denser and, as a result, make mammogram readings less clear.
While 3D mammograms have improved imaging technology to help navigate dense breast tissue, doctors often suggest postponing routine screening mammograms until after pregnancy if there are no symptoms or high-risk factors. However, if a lump or abnormality is found, your doctor may recommend immediate diagnostic imaging.
Mammograms are not done routinely if a woman becomes pregnant, yet there are specific situations where one might be unavoidable. Breast cancer in pregnancy does occur—1 in 3,000 times—but it's not common. If a lump is detected by a woman, she has constant breast pain and no explanation, or she is at high risk (e.g., strong history of breast cancer in her family or genetic defect such as BRCA1 or BRCA2), a physician will order a mammogram.
The process itself takes very little radiation exposure. The radiation employed by a mammogram is concentrated on the breast, and there is little to no radiation that reaches other areas of the body. A lead apron is also placed over the belly to shield the unborn child.
For pregnant women requiring breast imaging, physicians may initially suggest an ultrasound. In contrast to a mammogram, an ultrasound is not done with the use of radiation and is deemed safe for pregnant women.
An ultrasound of the breast can establish whether a lump is a fluid-filled cyst or a solid tumor that needs further investigation. Yet ultrasounds are not always diagnostic, and in certain instances, a mammogram or biopsy is needed to determine or rule out cancer.
Magnetic Resonance Imaging (MRI) is also an imaging choice but has some drawbacks. The majority of breast MRIs employ a contrast material called gadolinium, which is able to pass through the placenta and to the fetus. Although risks are not entirely clear, physicians usually do not use MRI with contrast unless necessary. Some practitioners may offer an MRI without contrast as an option.
Breast changes throughout pregnancy are normal, but finding a lump should never be taken lightly. If you notice a lump, alert your medical provider right away. They will conduct a clinical breast exam and potentially have you get an imaging study such as an ultrasound or mammogram to see whether anything needs to be done.
If imaging indicates a suspicious mass, a biopsy can be suggested. Core needle biopsy is the most frequently used and is safe during pregnancy. It consists of numbing the skin with local anesthetic and inserting a hollow needle into the area to obtain a small sample of tissue to be tested.
In the extremely uncommon event of a diagnosis of breast cancer while pregnant, therapy will be determined by the nature and extent of cancer and by how far along in pregnancy one is. The most frequent form of treatment is surgery—either mastectomy (surgical removal of the entire breast) or lumpectomy (surgical removal of the lump)—which is usually safe while pregnant.
Chemotherapy is also possible but usually only attempted after the first trimester, when it can damage developing fetal tissue. Radiation therapy is not used during pregnancy and is typically deferred until after giving birth. Hormonal therapy and targeted therapies are also omitted until after giving birth.
Yes, you can have a mammogram while you are breastfeeding. The radiation in a mammogram does not impact breast milk or hurt the baby. But breast density is still high during lactation, and this might complicate detection of abnormalities. To enhance image quality, physicians usually advise breastfeeding or pumping 30 minutes prior to the mammogram.
Routine screening mammograms are usually delayed in pregnancy unless there is a high-level concern.
If a lump is detected, an ultrasound is typically the initial imaging study done, with a mammogram being a consideration if additional assessment is necessary.
If breast cancer does develop during pregnancy, there are available treatment options that can be adjusted to keep the mother and infant safe.
Pregnancy is a period of significant change, and health issues particularly those involving breast health, are anxiety-provoking. Routine mammograms are typically postponed until after giving birth, but diagnostic testing can be done if necessary. The best you can do is discuss changes you notice in your breasts with your healthcare provider in an open manner. Early detection and prompt treatment can make a very big difference in the health of both mother and fetus.
Credit: AI generated image
Many people carry the thalassemia gene without knowing it because they may not have any symptoms. A simple carrier screening test before pregnancy can help couples understand risks and make informed decisions while planning parenthood.
Parenthood planning today is not only about financial preparation or healthy lifestyle changes, but also about understanding genetic health risks that can impact the child’s future. And one such condition that tends to go unnoticed is thalassemia carrier status.
Did you know? Many individuals discover they are carriers only after facing difficulties during pregnancy or after the birth of a child with thalassemia major.
Thalassemia is an inherited blood disorder that affects the production of hemoglobin, the protein in red blood cells that carries oxygen throughout the body. People who are carriers usually live normal and healthy lives and may not experience major symptoms. Because of this, many remain unaware of their carrier status for years.
However, it becomes a matter of concern when both partners are carriers of the thalassemia gene. In such cases, there is a huge risk that the child may inherit thalassemia major, a severe condition that may require lifelong blood transfusions, regular hospital visits, medications, and continuous medical care.
These are some of the challenges faced by families: So, challenges are that the thalassemia carrier status is often detected very late. Mild tiredness or anemia may be ignored or mistaken for iron deficiency, and many will not seek help.
So, couples do not consider genetic testing before marriage or pregnancy because they feel healthy and have no family history of the disease. When a child is born with thalassemia major, families may face stress, anxiety, repeated hospital visits, financial burden, and long-term treatment responsibilities. The condition can also affect the child’s growth, immunity, and overall quality of life.
This is why screening is important for couples: Carrier screening is a simple blood test that helps identify whether a person carries the thalassemia gene. If one partner tests positive, the other partner is advised to get tested as well.
Early screening before pregnancy helps couples understand their risks and explore available options with proper guidance. Thalassemia carrier screening is a small step that can make a major difference in parenthood planning.
Increasing awareness and encouraging timely testing can help families make informed decisions and reduce the burden of severe thalassemia in future generations. So, it is imperative to go for timely screening as advised by the expert and improve the quality of life.
Credit: iStock
Mental health issues among doctors remain a serious but rarely discussed concern within the medical community, said Dr. Cyriac Abby Philips, popularly known on social media as the LiverDoc.
In an exclusive interaction with HealthandMe, the noted hepatologist highlighted the rising cases of burnout, depression, and suicide among healthcare professionals and the urgent need to address them.
He stated that doctors are among the major communities affected by mental health disorders, although the topic is often ignored within the profession.
“We have had very senior doctors die by suicide because of burnout,” he said, citing incidents involving highly successful doctors recently reported from parts of India, including Kerala.
Liver Doc stressed that addressing doctors’ mental health is as important as treating patients’ mental health.
“A doctor who has good mental health will be a much better ally for the patient when it comes to treatment,” he said.
He also urged the medical community and regulatory authorities to introduce more interventions and support systems to prevent burnout and mental health disorders among doctors.
According to him, the emotional burden of treating critically ill patients and witnessing deaths regularly can deeply affect healthcare professionals.
“It’s depressing to treat patients and see them die. It’s depressing to see another human die,” he said.
The expert noted that doctors should find ways to openly discuss and process emotional stress and mental health struggles.
Dr. Philips also addressed the issue in his recently released book, The Liver Doctor: Stories of Love, Loss and Regeneration.
He told HealthandMe that he has “very thoroughly and in very raw format addressed in the book” the mental health disorders affecting doctors, as it directly impacts patient care.
“Like every other doctor, I have also gone through that, and it's depressing to treat patients and see them die. I have this book to channelize that, and I feel less burdened when I do that, but other doctors also should find ways to do this. So this book also tells doctors to be more open about their mental health,” he said.
Doctors in teaching hospitals often endure long, unregulated shifts with little time for rest, especially during residency. Such exhausting work conditions not only increase the risk of medical errors but also significantly contribute to burnout, emotional exhaustion, and mental health problems among young doctors.
As per a recent nationwide survey on doctors’ mental health and morale, nine in ten doctors said they would not want their children to become physicians.
Also read: Global Mental Disorders Double In 33 Years, Affecting 1.2 Billion People: Study
The study, conducted by the Debabrata Mitalee Auro Foundation, surveyed 1,208 doctors across metropolitan cities and smaller towns over six months and found deep levels of burnout, fear of violence, and rising medico-legal anxiety among medical professionals.
Further, the Parliamentary Standing Committee on Health and Family Welfare also raised concerns over “excessive continuous duty hours” for junior and senior resident doctors in April.
In its latest report, the panel warned that fatigue-driven errors and burnout could compromise care.
The Panel recommended that the government introduce and strictly enforce a formal “Clinical Duty Hours Regulation” policy. This would mandate fixed rest periods and monitored duty rosters, with oversight mechanisms to prevent violations.
Credit: iStock
India’s cell and gene therapy ecosystem is beginning to attract a different kind of attention that is driven not just by healthcare demand, but by proprietary science and platform-led innovation.
For investors, however, the larger story may not be the funding round itself. It may be the problem the company is trying to solve.
CAR-T therapies have transformed outcomes for several difficult-to-treat blood cancers globally. But despite strong initial responses, relapse remains one of the field’s biggest limitations. One reason is antigen escape, which means cancer cells can change the markers that therapies use to identify them, making them harder to detect over time.
In an analysis of 4,129 CAR-T treated patients, relapse remained a substantial issue after single-target therapy, with 42.1% of relapses associated with loss of the CD19 target itself. The finding points to a larger issue: precision may not be enough if therapies lose visibility over time.
The response increasingly appears to be a move toward multi-target and more durable platforms. A bispecific CAR-T platform designed to recognize more than one tumor marker, to reduce relapse is crucial.
The science itself is becoming increasingly platform-oriented. Beyond broader targeting, recent work explored why immune cells themselves lose effectiveness over time and identified pathways associated with stronger persistence and memory. While still early, the broader implication is that future therapies may need to be designed not only to attack disease, but also to remain active longer.
For India, that creates a larger opportunity. Historically, advanced therapies such as CAR-T have remained expensive and heavily dependent on technologies developed elsewhere. The aim is to significantly reduce treatment costs while building indigenous capabilities across design and manufacturing.
The shift matters because biotech investing is increasingly moving beyond services and generics toward intellectual property and platform science. The transition from bedside observations to translational platforms may be where the next phase of healthcare innovation and investment gets built.
© 2024 Bennett, Coleman & Company Limited